This is therefore a comparing of the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership in Acorda Therapeutics Inc. (NASDAQ:ACOR) and Unity Biotechnology Inc. (NASDAQ:UBX). The two are both Biotechnology companies that compete with one another.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acorda Therapeutics Inc. | 12 | 0.80 | N/A | -0.43 | 0.00 |
| Unity Biotechnology Inc. | 9 | 0.00 | N/A | -6.43 | 0.00 |
Table 1 shows the gross revenue, earnings per share and valuation for Acorda Therapeutics Inc. and Unity Biotechnology Inc.
Profitability
Table 2 demonstrates the return on assets, return on equity and net margins of Acorda Therapeutics Inc. and Unity Biotechnology Inc.
| Net Margins | Return on Equity | Return on Assets | |
| Acorda Therapeutics Inc. | 0.00% | -1% | -0.4% |
| Unity Biotechnology Inc. | 0.00% | -46.4% | -42.4% |
Liquidity
The current Quick Ratio of Acorda Therapeutics Inc. is 4 while its Current Ratio is 4.3. Meanwhile, Unity Biotechnology Inc. has a Current Ratio of 13.7 while its Quick Ratio is 13.7. Unity Biotechnology Inc. is better positioned to pay off its short-term and long-term debts than Acorda Therapeutics Inc.
Analyst Ratings
Ratings and Recommendations for Acorda Therapeutics Inc. and Unity Biotechnology Inc. can be find in next table.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Acorda Therapeutics Inc. | 0 | 1 | 1 | 2.50 |
| Unity Biotechnology Inc. | 0 | 0 | 1 | 3.00 |
Acorda Therapeutics Inc. has a 386.73% upside potential and an average target price of $33. Competitively the consensus target price of Unity Biotechnology Inc. is $21, which is potential 205.23% upside. The information presented earlier suggests that Acorda Therapeutics Inc. looks more robust than Unity Biotechnology Inc. as far as analyst view.
Institutional & Insider Ownership
Acorda Therapeutics Inc. and Unity Biotechnology Inc. has shares owned by institutional investors as follows: 0% and 72.3%. Insiders owned roughly 1.5% of Acorda Therapeutics Inc.’s shares. Comparatively, insiders own roughly 12.22% of Unity Biotechnology Inc.’s shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Acorda Therapeutics Inc. | -4% | -5.37% | -26.85% | -43.46% | -54.52% | -27.6% |
| Unity Biotechnology Inc. | 6.65% | 22.53% | -18.71% | -21.98% | -37.12% | -42.8% |
For the past year Acorda Therapeutics Inc. has stronger performance than Unity Biotechnology Inc.
Summary
Acorda Therapeutics Inc. beats Unity Biotechnology Inc. on 7 of the 9 factors.
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in ParkinsonÂ’s disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in ParkinsonÂ’s disease; SYN120, which is in Phase II clinical trial to treat ParkinsonÂ’s disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and WomenÂ’s Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
